Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Assets (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Non-Current Assets for 13 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 129.89% to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.1 million through Dec 2025, up 30.91% year-over-year, with the annual reading at $9.6 million for FY2025, 129.89% up from the prior year.
  • Non-Current Assets for Q4 2025 was $9.6 million at Niagen Bioscience, up from $4.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $9.6 million in Q4 2025, with the low at $4.2 million in Q4 2024.
  • Average Non-Current Assets over 5 years is $6.5 million, with a median of $6.8 million recorded in 2023.
  • The sharpest move saw Non-Current Assets plummeted 30.37% in 2024, then surged 129.89% in 2025.
  • Over 5 years, Non-Current Assets stood at $8.9 million in 2021, then fell by 16.17% to $7.5 million in 2022, then decreased by 27.5% to $5.4 million in 2023, then decreased by 23.09% to $4.2 million in 2024, then skyrocketed by 129.89% to $9.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $9.6 million, $4.5 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.